Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
94.73
+0.13 (0.14%)
Nov 21, 2024, 10:59 AM EST - Market open
Axsome Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 338.46 | 270.6 | 50.04 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | 51.47% | 440.80% | - | - | - | - | Upgrade
|
| Cost of Revenue | 30.17 | 26.07 | 4.1 | - | - | - | Upgrade
|
| Gross Profit | 308.29 | 244.54 | 45.94 | - | - | - | Upgrade
|
| Selling, General & Admin | 384.9 | 323.12 | 159.25 | 66.65 | 28.9 | 13.6 | Upgrade
|
| Research & Development | 162.87 | 97.94 | 57.95 | 58.06 | 70.19 | 53.51 | Upgrade
|
| Operating Expenses | 554.16 | 427.44 | 221.34 | 124.71 | 99.09 | 67.11 | Upgrade
|
| Operating Income | -245.87 | -182.91 | -175.4 | -124.71 | -99.09 | -67.11 | Upgrade
|
| Interest Expense | -5.06 | -6.45 | -7.34 | -5.7 | -2.57 | -1.24 | Upgrade
|
| EBT Excluding Unusual Items | -250.93 | -189.36 | -182.74 | -130.4 | -101.65 | -68.35 | Upgrade
|
| Merger & Restructuring Charges | - | - | -1.1 | - | - | - | Upgrade
|
| Other Unusual Items | -60.35 | -48.92 | -3.3 | - | -1.25 | - | Upgrade
|
| Pretax Income | -311.28 | -238.28 | -187.13 | -130.4 | -102.9 | -68.35 | Upgrade
|
| Income Tax Expense | -0.33 | 0.96 | - | - | - | - | Upgrade
|
| Net Income | -310.96 | -239.24 | -187.13 | -130.4 | -102.9 | -68.35 | Upgrade
|
| Net Income to Common | -310.96 | -239.24 | -187.13 | -130.4 | -102.9 | -68.35 | Upgrade
|
| Shares Outstanding (Basic) | 48 | 45 | 41 | 38 | 37 | 34 | Upgrade
|
| Shares Outstanding (Diluted) | 48 | 45 | 41 | 38 | 37 | 34 | Upgrade
|
| Shares Change (YoY) | 7.10% | 11.73% | 8.07% | 1.11% | 9.37% | 26.55% | Upgrade
|
| EPS (Basic) | -6.53 | -5.27 | -4.60 | -3.47 | -2.77 | -2.01 | Upgrade
|
| EPS (Diluted) | -6.53 | -5.27 | -4.60 | -3.47 | -2.77 | -2.01 | Upgrade
|
| Free Cash Flow | -132.82 | -145.66 | -117.21 | -108.53 | -78.5 | -46.39 | Upgrade
|
| Free Cash Flow Per Share | -2.79 | -3.21 | -2.88 | -2.89 | -2.11 | -1.36 | Upgrade
|
| Gross Margin | 91.09% | 90.37% | 91.81% | - | - | - | Upgrade
|
| Operating Margin | -72.65% | -67.59% | -350.54% | - | - | - | Upgrade
|
| Profit Margin | -91.87% | -88.41% | -373.99% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -39.24% | -53.83% | -234.25% | - | - | - | Upgrade
|
| EBITDA | -244.62 | -182.45 | -175.14 | -124.63 | -99.06 | -67.07 | Upgrade
|
| EBITDA Margin | -72.28% | -67.42% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 1.25 | 0.46 | 0.26 | 0.08 | 0.02 | 0.04 | Upgrade
|
| EBIT | -245.87 | -182.91 | -175.4 | -124.71 | -99.09 | -67.11 | Upgrade
|
| EBIT Margin | -72.65% | -67.59% | - | - | - | - | Upgrade
|
| Revenue as Reported | 338.46 | 270.6 | 50.04 | - | - | - | Upgrade
|
| Advertising Expenses | - | 100.3 | 35.3 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.